Abstract
Drug discovery is a complex process that includes the identification of biological targets as well as the identification of leads that aim at altering or inhibiting the function of a particular target. The budding yeast Saccharomyces cerevisiae has long been recognized as a valuable model organism for studies of eukaryotic cells since many of the basic cellular processes between yeast and humans are highly conserved. In this review, we highlight emerging yeast-based functional genomic and proteomic technologies that are advancing the utility of yeast as a model organism in the drug-discovery process. These approaches include the utilization of yeast deletion strain collection, synthetic genetic array combined with chemical genomics, variations of the yeast two-hybrid system, yeast biosensor assay, and protein microarrays. Although still at an early stage, these technologies show promise as novel and useful methods for development of target-specific therapeutic approaches.
Keywords: drug discovery, yeast two hybrid system, genomics, proteomics
Current Proteomics
Title: Drug Discovery Using Yeast as a Model System: A Functional Genomic and Proteomic View
Volume: 2 Issue: 1
Author(s): Daniel Auerbach, Anthony Arnoldo, Boris Bogdan, Michael Fetchko and Igor Stagljar
Affiliation:
Keywords: drug discovery, yeast two hybrid system, genomics, proteomics
Abstract: Drug discovery is a complex process that includes the identification of biological targets as well as the identification of leads that aim at altering or inhibiting the function of a particular target. The budding yeast Saccharomyces cerevisiae has long been recognized as a valuable model organism for studies of eukaryotic cells since many of the basic cellular processes between yeast and humans are highly conserved. In this review, we highlight emerging yeast-based functional genomic and proteomic technologies that are advancing the utility of yeast as a model organism in the drug-discovery process. These approaches include the utilization of yeast deletion strain collection, synthetic genetic array combined with chemical genomics, variations of the yeast two-hybrid system, yeast biosensor assay, and protein microarrays. Although still at an early stage, these technologies show promise as novel and useful methods for development of target-specific therapeutic approaches.
Export Options
About this article
Cite this article as:
Auerbach Daniel, Arnoldo Anthony, Bogdan Boris, Fetchko Michael and Stagljar Igor, Drug Discovery Using Yeast as a Model System: A Functional Genomic and Proteomic View, Current Proteomics 2005; 2 (1) . https://dx.doi.org/10.2174/1570164053507790
DOI https://dx.doi.org/10.2174/1570164053507790 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologically Active Insulin-derived Peptides
Protein & Peptide Letters Recent Developments in the Virology and Antiviral Research of Severe Acute Respiratory Syndrome Coronavirus
Infectious Disorders - Drug Targets The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Proteomics Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Current Molecular Medicine Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Vitamin D, Pit-1, GH, and PRL: Possible Roles in Breast Cancer Development
Current Medicinal Chemistry NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design From Small to Powerful: The Fragments Universe and its “Chem-Appeal”
Current Medicinal Chemistry Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer
Current Pharmaceutical Design The RING-Finger Protein Haprin: Domains and Function in the Acrosome Reaction
Current Protein & Peptide Science Nucleocytoplasmic Glycosylation, O-linked β-N-Acetylglucosamine
Current Organic Chemistry Phosphoprotein Phosphatase 1 Complexes in Spermatogenesis
Current Molecular Pharmacology Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
Current Drug Targets The Role and Predictive Value of Cytokines in Atherosclerosis and Coronary Artery Disease
Current Medicinal Chemistry